Victory Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Victory Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-172,914	Closed	-$18.6M	–	2645
2023 Q1	$18.6M	Buy	172,914 +54,507	+46%	+$6.27M	0.02%	814
2022 Q4	$13M	Buy	118,407 +110,292	+1,359%	+$7.15M	0.02%	939
2022 Q3	$479K	Buy	+8,115	New	+$371K	﹤0.01%	2072

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Victory Capital Management's RXDX Position: Q2 2023 in Review

Victory Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 172,914 shares — an estimated $18.6M sold.

Victory Capital Management first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $18.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Victory Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Victory Capital Management sold 172,914 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $18.6M.
Victory Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Victory Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $18.6M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Victory Capital Management's 13F filing for Q2 2023, filed 27 Jul 2023.